ZA201405070B - 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors - Google Patents
1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitorsInfo
- Publication number
- ZA201405070B ZA201405070B ZA2014/05070A ZA201405070A ZA201405070B ZA 201405070 B ZA201405070 B ZA 201405070B ZA 2014/05070 A ZA2014/05070 A ZA 2014/05070A ZA 201405070 A ZA201405070 A ZA 201405070A ZA 201405070 B ZA201405070 B ZA 201405070B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyrrolo
- kinase inhibitors
- pyridine derivatives
- pyridine
- derivatives
- Prior art date
Links
- 150000005258 1H-pyrrolo(2,3-b)pyridines Chemical class 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1201566.5A GB201201566D0 (en) | 2012-01-30 | 2012-01-30 | New chemical compounds |
| PCT/GB2013/050212 WO2013114113A1 (en) | 2012-01-30 | 2013-01-30 | 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201405070B true ZA201405070B (en) | 2016-03-30 |
Family
ID=45876325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2014/05070A ZA201405070B (en) | 2012-01-30 | 2014-07-11 | 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10000481B2 (https=) |
| EP (1) | EP2809670B1 (https=) |
| JP (1) | JP6199316B2 (https=) |
| CN (4) | CN111484493A (https=) |
| AU (1) | AU2013213954B2 (https=) |
| BR (1) | BR112014018795B1 (https=) |
| CA (1) | CA2862940C (https=) |
| DK (1) | DK2809670T3 (https=) |
| EA (1) | EA026657B1 (https=) |
| ES (1) | ES2637340T3 (https=) |
| GB (1) | GB201201566D0 (https=) |
| HK (1) | HK1200447A1 (https=) |
| HU (1) | HUE035332T2 (https=) |
| IL (1) | IL233595B (https=) |
| IN (1) | IN2014DN06104A (https=) |
| MX (1) | MX352927B (https=) |
| NZ (1) | NZ627361A (https=) |
| PL (1) | PL2809670T3 (https=) |
| PT (1) | PT2809670T (https=) |
| WO (1) | WO2013114113A1 (https=) |
| ZA (1) | ZA201405070B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201201566D0 (en) * | 2012-01-30 | 2012-03-14 | Vernalis R&D Ltd | New chemical compounds |
| AR090789A1 (es) * | 2012-04-23 | 2014-12-10 | Genentech Inc | Intermediarios y procesos para la preparacion de compuestos |
| KR102325163B1 (ko) * | 2013-08-22 | 2021-11-11 | 제넨테크, 인크. | 화합물의 제조 방법 |
| CN104829609B (zh) * | 2014-02-11 | 2016-08-03 | 北大方正集团有限公司 | 取代的吡啶并嘧啶化合物及其制备方法和应用 |
| MA41559A (fr) * | 2015-09-08 | 2017-12-26 | Taiho Pharmaceutical Co Ltd | Composé de pyrimidine condensé ou un sel de celui-ci |
| US10032914B2 (en) * | 2015-10-20 | 2018-07-24 | Taiwan Semiconductor Manufacturing Co., Ltd. | Semiconductor device and manufacturing method thereof |
| ES2775751T3 (es) | 2016-02-23 | 2020-07-28 | Taiho Pharmaceutical Co Ltd | Nuevo compuesto de pirimidina condensada o sal del mismo |
| JP7033143B2 (ja) | 2017-08-21 | 2022-03-09 | 大鵬薬品工業株式会社 | Ｄｃｔｎ１タンパク質とｒｅｔタンパク質との融合タンパク質 |
| TW202043198A (zh) | 2019-01-17 | 2020-12-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關之病況的化合物及組合物 |
| CN111518096B (zh) | 2019-02-02 | 2022-02-11 | 江苏威凯尔医药科技有限公司 | 两面神激酶jak家族抑制剂及其制备和应用 |
| US12428395B2 (en) | 2019-08-01 | 2025-09-30 | Sperogenix Therapeutics Limited | Heterocyclic compounds as kinase inhibitor and uses thereof |
| IT202000005527A1 (it) * | 2020-03-16 | 2021-09-16 | Univ Degli Studi Di Trento | Trattamento terapeutico di cromatinopatie |
| PY2157405A (es) * | 2020-07-15 | 2022-04-22 | Ifm Due Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad del sting |
| EP4182030A1 (en) * | 2020-07-15 | 2023-05-24 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| EP4182310A1 (en) | 2020-07-15 | 2023-05-24 | IFM Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| TW202235073A (zh) | 2021-01-08 | 2022-09-16 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關的病狀之化合物及組合物 |
| UY39892A (es) | 2021-08-10 | 2023-03-31 | Novartis Pharma Ag | Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING |
| WO2023137034A1 (en) * | 2022-01-12 | 2023-07-20 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| CN116554170A (zh) * | 2023-04-26 | 2023-08-08 | 上海大学 | 4-氟-7-氮杂吲哚的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1012976A (en) * | 1909-03-25 | 1911-12-26 | Adolf Bordt | Adding-machine. |
| WO2003028724A1 (en) | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| US7531553B2 (en) * | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
| CA2546754A1 (en) * | 2003-11-21 | 2005-06-09 | Array Biopharma Inc. | Akt protein kinase inhibitors |
| US8841304B2 (en) * | 2008-01-08 | 2014-09-23 | Array Biopharma, Inc. | Pyrrolopyridines as kinase inhibitors |
| DK2294065T3 (da) * | 2008-01-22 | 2014-04-28 | Vernalis R&D Ltd | Indolyl-pyridonderivater med checkpoint kinase 1 inhibitorisk aktivitet |
| AR071717A1 (es) * | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| BRPI0909957A2 (pt) | 2008-06-11 | 2016-04-19 | Genentech Inc | "composto, composição farmacêutica, método de inibir o crescimento anormal de células ou de tratar um distúrbio hiperproliferativo em um mamífero, método de tratamento do câncer em um mamífero" |
| EP2461869B1 (en) * | 2009-08-06 | 2013-08-21 | Merck Patent GmbH | Novel bicyclic urea compounds |
| WO2011146313A1 (en) * | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
| GB201201566D0 (en) * | 2012-01-30 | 2012-03-14 | Vernalis R&D Ltd | New chemical compounds |
-
2012
- 2012-01-30 GB GBGB1201566.5A patent/GB201201566D0/en not_active Ceased
-
2013
- 2013-01-30 DK DK13703121.7T patent/DK2809670T3/en active
- 2013-01-30 PT PT137031217T patent/PT2809670T/pt unknown
- 2013-01-30 PL PL13703121T patent/PL2809670T3/pl unknown
- 2013-01-30 CN CN202010405942.3A patent/CN111484493A/zh active Pending
- 2013-01-30 US US14/375,353 patent/US10000481B2/en active Active
- 2013-01-30 EP EP13703121.7A patent/EP2809670B1/en active Active
- 2013-01-30 CA CA2862940A patent/CA2862940C/en active Active
- 2013-01-30 CN CN201380014717.5A patent/CN104203948A/zh active Pending
- 2013-01-30 EA EA201491376A patent/EA026657B1/ru not_active IP Right Cessation
- 2013-01-30 NZ NZ627361A patent/NZ627361A/en not_active IP Right Cessation
- 2013-01-30 HU HUE13703121A patent/HUE035332T2/en unknown
- 2013-01-30 HK HK15100794.1A patent/HK1200447A1/xx unknown
- 2013-01-30 IN IN6104DEN2014 patent/IN2014DN06104A/en unknown
- 2013-01-30 WO PCT/GB2013/050212 patent/WO2013114113A1/en not_active Ceased
- 2013-01-30 JP JP2014555310A patent/JP6199316B2/ja not_active Expired - Fee Related
- 2013-01-30 BR BR112014018795-9A patent/BR112014018795B1/pt not_active IP Right Cessation
- 2013-01-30 CN CN201610920724.7A patent/CN107011341A/zh active Pending
- 2013-01-30 CN CN201610920720.9A patent/CN106866658B/zh not_active Expired - Fee Related
- 2013-01-30 MX MX2014009112A patent/MX352927B/es active IP Right Grant
- 2013-01-30 ES ES13703121.7T patent/ES2637340T3/es active Active
- 2013-01-30 AU AU2013213954A patent/AU2013213954B2/en active Active
-
2014
- 2014-07-10 IL IL233595A patent/IL233595B/en active IP Right Grant
- 2014-07-11 ZA ZA2014/05070A patent/ZA201405070B/en unknown
-
2018
- 2018-06-15 US US16/009,439 patent/US10889582B2/en active Active
-
2020
- 2020-11-30 US US17/107,176 patent/US20210206762A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201405070B (en) | 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors | |
| ZA201906379B (en) | 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | |
| PL2857404T3 (pl) | POCHODNE IMIDAZO[1,2-b]PIRYDAZYNY JAKO INHIBITORY KINAZY | |
| IL235819B (en) | Derivatives of [(2-fluoro-3-amino)phenyl]carbonyl-pyrrolo [3,2-b]pyridin-3-yl and a method for their preparation | |
| ZA201507874B (en) | 2-aminopyrido[4,3-d]pyrimidin-5-one derivatives and their use as wee-1 inhibitors | |
| IL238493A0 (en) | Amino-substituted imidazo[a–2,1]pyridinecarboxamides and their use | |
| PT2812337T (pt) | Derivados de furo[3,2-b]piridina como inibidores de tbk1 e ikk | |
| ZA201506182B (en) | Imidazo[4,5-c]pyridine and pyrrolo[2,3-c]pyridine derivatives as ssao inhibitors | |
| ZA201307511B (en) | Pyrido [2,3-b] pyrazine derivatives and their therapeutical uses | |
| SG11201408816QA (en) | 3-(PYRAZOLYL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS | |
| EP2970278A4 (en) | Pyrrolo [2,3] PYRIDINE KINASE INHIBITORS CDK9- | |
| IL232717A0 (en) | 3-cyanoaryl-h1-pyrrolo[b-3,2]pyridine derivatives | |
| SG11201500883YA (en) | 5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS |